
CAS SciFinder

跟踪学科前沿发现 助力科研创新







大纲

- CAS SciFinder数据介绍
- 纳米储能材料的研究调研与追踪
- 生物、催化和医药研究的物质根基
- 结构视角下的专利风险规避
- 制备反应研究的技术支撑







CAS具有最全面的学科连接内容合集

ACTIVE PHARMA INGREDIENT COSMETIC FORMULATIONS **INFRARED DATA** ANALYTICAL METHODS PROTOCOLS **GLOBAL REGULATIONS** SPECTRAL DATA STRUCTURES REACTIONS PHARMACOLOGY / TOXICOLOGY **PROCESSES** STRUCTURE-ACTIVITY-RELATIONSHIP **PROPERTIES** IP CLAIMS INGREDIENT FUNCTIONS **DNA / RNA SEQUENCES** MARKUSH DISEASES **UVCB SUBSTANCES CELL LINES / TYPES** NMR DATA **FORMULATIONS** POLYMER PROPERTIES BIOMOLECULE ISOLATION AGRICULTURE FORMULATIONS **TARGETS** MASS SPEC DATA **PROTOCOLS ORGANOMETALLICS / INORGANICS** BIOASSAYS

55K
scientific journals
and documents

Over **269**

million substances

Over

50

languages translated 64
patent offices
worldwide





CAS SciFinder中覆盖的内容合集

CAS References

>5600万专利、期刊、学['] 位论文、图书、报告等

64家专利授权机构的专利

回溯到19世纪早期

CAS Reactions

>1.47亿条反应信息 回溯到1840年 CAS Markush

>130万有机、金属有机

马库什结构

回溯到1961年

Medline

>3200万篇生物学、

生物医学文献,

>5400种刊物,

回溯至1946年

CAS Commercial Sources

全球化学品供应商及化学 品信息。

数百万商用化学品数百万独特的物质

来源:

https://www.cas.org/cas-data https://www.cas.org/about/cas-content

>2.69亿个独特物质

包括约7000万条生物序列

约80亿条物质属性值和光谱

150个化学管制品目录

15个国际和国家目录,

包括TSCA





CAS SciFinder覆盖的学科


- 生物化学:

- 农化产品管控信息、生化遗传学、发酵、免疫化学、药理学
- 有机化学各领域:
 - 氨基酸、生物分子、碳水化合物、有机金属化合物、类固醇
- 大分子化学各领域:
 - 一纤维素、木质素、造纸;涂料、墨水
 - 染料、有机颜料; 合成橡胶; 纺织品、纤维
- 一 应用化学各领域:
 - 大气污染、陶瓷、精油、化妆品、化石燃料、黑色金属、合金
- 一物理、无机、分析化学各领域:
 - ■表面化学、催化剂、相平衡、核现象、电化学



CAS科学家的智力标引


comprehensive search results.














Androst-4-en-3-one, 17-hydroxy-17methyl-, (17β)-

CAS科学家利用人类智慧对公开内容进行揭示,使相关信息更容易被挖掘





大纲


- CAS SciFinder数据介绍
- 纳米储能材料的研究调研与追踪
- 生物、催化和医药研究的物质根基
- 结构视角下的专利风险规避
- 制备反应研究的技术支撑








碳纳米管储能材料的主题检索








文献结果候选项












设置提醒,及时跟踪最新研究进展












文献结果分析



Analyze by: Author Name	•
Peng Huisheng	46
Zhang Qiang	30
Wei Fei	29
Hu Liangbing	25
Cao Anyuan	22
Gogotsi Yury	22
Liu Chang	21
Li Feng	19
Zhang Xiaogang	19
Chen Jun	18
Show More	

Analyze by: Company-Organization	•
Chinese Academy of Sciences, Peop Rep China	77
Tsinghua university, Peop Rep China	69
Fudan University, Peop Rep China	64
Massachusetts Institute of Technology, USA	40
Nanyang Technological University, Singapore	35
University of California, USA	33
USA	26
Zhejiang University, Peop Rep China	24
Donghua University, Peop Rep China	23
Korea University, S Korea	22
Chau Maus	


Analyze by: Document Type	•
Journal	2413
Online Computer File	1748
Patent	890
General Review	337
Conference	292
Meeting Abstract	211
Article	79
JOURNAL ARTICLE	79
Computer Optical Disk	71
RESEARCH SUPPORT NONUS GOVT	32
Show More	


Analyze by: Journal Name	•
Faming Zhuanli Shenqing	391
PCT Int. Appl.	192
U.S. Pat. Appl. Publ.	152
Journal of Materials Chemistry A: Materials for Energy and Sustainability	146
ACS Applied Materials & Interfaces	87
RSC Advances	84
Electrochimica Acta	74
Journal of Power Sources	70
Advanced Materials (Weinheim, Germany)	62
Carbon	59
Show More	





文献检索结果分析: CA Section Title





电化学、放射及热能技术 电现象 表面化学和胶体 硅酸盐 电化学 工业无机化合物 塑料制备和加工


普诵物理化学


织物和纤维





通过Index Term,可纵览或精炼研究点信息











Refine: 二次限定,例如精炼蓄电池方面的研究文献








Categorize: 精准获取特定的研究信息








Technology: 精准获取制备的能源&燃料,材料&产品等信息











Refine: 筛选专利文献







点击文献标题,可获取文献详情








文献详情

1. Composite electrode material, preparation method and application thereof

By: Wang, Yue; Liang, Minghui; Jiang, Peng; Zhang, Xianfeng; Wei, Hang; Li, Xin; Liu, Yongguang Assignee: National Center for Nanoscience and Technology, Peop. Rep. China

The title method comprises mixing coordination dissolved metal oxide and/or hydroxide soln. with carbon material, through evapn. of ligand soln., in situ growing metal oxide and/or metal hydroxide on carbon material surface, and obtaining the composite electrode material. The method is simple to operate, has low cost, is green and environmental protection, without aftertreatment, and provides possibility for the industrialized scale operation of electrode materials. The composite electrode material propor, by the method of the invention has excellent property in terms of power storage. Such as the nickel hydroxide-activated carbon composite electrode material with 5% of loading amt. prepd. by the method of the invention under sweep speed of 5 mV/s, the complete electrode specific discharge capacity reaches 294 F/g, and the active substance specific capacity is up to 4917 F/g.



QUICK LINKS

0 Tags, 0 Comments

PATENT INFORMATION

Nov 17, 2017 CN 107359054 A

APPLICATION

May 9, 2016 CN 2016-10301475

PRIORITY

May 9, 2016 CN 2016-10301475

SOURCE

Faming Zhuanli Shenqing 13pp. Patent 2017

CODEN: CNXXEV

ACCESSION NUMBER

2017:1811624 CAN168:7562 CAPLUS

LANGUAGE

Chinese

Patent Information

Patent No.		Kind	Language	Date	Application No.	Date
CN 107359054	PATENTPAK	A	AVE-VEV	Nov 17, 2017	CN 2016-10301475	May 9, 2016
Priority Application						
CN 2016-10301475				May 9, 2016		





文献详情

Indexing

学科领域

Electrochemical, Radiational, and Thermal Energy Technology (Section52-2)

Concepts

Batteries Carbon nanotubes
Electrodes Energy storage
Energy storage systems Evaporation
Lithium-ion secondary batteries Nanostructured materials
Supercapacitors

composite electrode material, prepn. method and application thereof

Carbon fibers

composite electrode material, prepn. method and application thereof

Physical, engineering or chemical process; Properties; Technical or engineered material use; Process;

标准概念词列表

物质CAS RN, 物质名称

重要的物质列表

Substances

7440-44-0 Activated carbon, uses Q Page 2 in PATENTPAK

activated; composite electrode material, prepn. method and application thereof

Physical, engineering or chemical process; Properties; Technical or engineered material use; Process; Uses

1313-99-1 Nickel oxide, uses 9	Page 2 in PATENTPAK
1314-13-2 Zinc oxide, uses 9	Page 2 in PATENTPAK
1335-25-7 Lead oxide 9	Page 2 in PATENTPAK
1344-69-0 Copper hydroxide 9	Page 2 in PATENTPAK
1344-70-3 Copper oxide 9	Page 2 in PATENTPAK
11104-61-3 Cobalt oxide 9	Page 2 in PATENTPAK
11113-84-1 Ruthenium oxide 9	Page 2 in PATENTPAK
11129-60-5 Manganese oxide 9	Page 2 in PATENTPAK
12054-48-7 Nickel hydroxide 9	Page 2 in PATENTPAK
12626-88-9 Manganese hydroxide 9	Page 2 in PATENTPAK
12645-46-4 Iridium oxide	Page 2 in PATENTPAK
12672-51-4 Cobalt hydroxide 9	Page 2 in PATENTPAK
12673-77-7 Silver hydroxide 9	Page 2 in PATENTPAK
19783-14-3 Lead hydroxide 9	Page 2 in PATENTPAK
20427-58-1 Zinc hydroxide 9	Page 2 in PATENTPAK
20667-12-3 Silver oxide 9	Page 2 in PATENTPAK
56321-86-9 Ruthenium hydroxide 9	Page 2 in PATENTPAK
57425-17-9 Iridium hydroxide 9	Page 2 in PATENTPAK

composite electrode material, prepn. method and application thereof

Physical, engineering or chemical process; Properties; Technical or engineered material use; Process; Uses

74-89-5 Methylamine, uses 9 Page 2 in PATENTPAK

物质功能描述

定位信息





大纲


- CAS SciFinder数据介绍
- 纳米储能材料的研究调研与追踪
- 生物、催化和医药研究的物质根基
- 结构视角下的专利风险规避
- 制备反应研究的技术支撑







结构编辑器的使用



重要绘制工具注释



选择可变基团



自定义R基团



重复工具



取代位置可变



锁环工具




锁原子工具





有机化合物: 通式结构的绘制



要求:

- 1.两个环系不能与其他环(系)形成新的稠环(系)或桥环(系);
- 2. 六元含氮环上可出现互变异构, 比如烯酮;
- 3. 六元碳环上有一个F取代和一个五至六元的饱和或非饱和杂环取代。 杂环的1,3位为N原子,R1为C或O;
- 4. 六元碳环上有且只有杂环和F取代, 且连接位点不确定。


















根据分子式检索无机化合物




无机金属盐:金属离子和阴离子间用点(.)分开








根据络合物的结构来检索配位化合物












根据配体结构和中心金属原子来检索配位化






















































































物质标识符检索








物质结果








点击CAS RN获取物质详情









大纲

- CAS SciFinder数据介绍
- 纳米储能材料的研究调研与追踪
- 生物、催化和医药研究的物质根基
- 结构视角下的专利风险规避
- 制备反应研究的技术支撑







结构检索的原理与示例

US005480883A

5,480,883

BIS MONO- AND BICYCLIC ARYL AND HETEROARYL COMPOUNDS WHICH INHIBIT EGF AND/OR PDGF RECEPTOR TYROSINE KINASE

BACKGROUND OF THE INVENTION

This application is a continuation-in-part application of U.S. Ser. No. 07/988,515, filed Dec. 10, 1992, now abandoned which is a continuation-in-part application of U.S. Ser. No. 07/698,420, filed May 10, 1991 now abandoned and a continuation-in-part application of PCT International Application Ser. No. PCT/US92/03736 filed May 6, 1992.

FIELD OF THE INVENTION

This invention relates to the modulation and/or inhibition of cell signaling, cell proliferation, cell inflammatory response, the control of abnormal cell growth and cell reproduction. More specifically, this invention relates to the use of bis mono- and/or bicyclic aryl and/or heteroaryl 20 compounds in inhibiting cell proliferation, including compounds which are useful protein tyrosine kinase (PTK)

Normal cellular reproduction is believed to be triggered by the exposure of the cellular substrate to one or more 25 tyrosine kinase inhibition activity wherein each aryl group is growth factors, examples of which are insulin, epidermal growth factor (EGF) and platelet-derived growth factor (PDGF). Such growth factor receptors are imbedded in and penetrate through the cellular membrane. The initiation of cellular reproduction is believed to occur when a growth 3 factor binds to the corresponding receptor on the external surface of the cellular membrane. This growth factor-receptor binding alters the chemical characteristics of that portion of the receptor which exists within the cell and which functions as an enzyme to catalyze phosphorylation of either 35 an intracellular substrate or the receptor itself, the latter being referred to as autophosphorylation. Examples of such phosphorylation enzymes include tyrosine kinases, which catalyze phosphorylation of tyrosine amino acid residues of substrate proteins.

Many disease states are characterized by the uncontrolled reproduction of cells. These disease states involve a variety of cell types and include disorders such as leukemia, cancer, psoriasis, inflammatory diseases, bone diseases, atherosclerosis and restenosis occuring subsequent to angioplastic procedures. The inhibition of tyrosine kinase is believed to have utility in the control of uncontrolled cellular reproduction, i.e., cellular proliferative disorders.

Initiation of autophosphorylation, i.e., phosphorylation of the growth factor receptor itself, and of the phosphorylation of a host of intracellular substrates are some of the biochemical events which are involved in mediator release mitogenesis and cell proliferation. Autophosphorylation of the insulin receptor and phosphorylation of substrate proteins by other receptors are the earliest identifiable biochemical hormonal responses.

Elimination of the protein tyrosine kinase (PTK) activity of the insulin receptor and of the epidermal growth factor (EGF) receptor by site-directed mutagenesis of the cellular genetic material which is responsible for generation of insulin and EGF results in the complete elimination of the receptor's biological activity. This is not particularly desirable because insulin is needed by the body to perform other biological functions which are not related to cell proliferation. Accordingly, compounds which inhibit the PTK portion of the EGF and/or PDGF receptor at concentrations less than

the concentrations needed to inhibit the PTK portion of the insulin receptor could provide valuable agents for selective treatment of cell proliferation disorders.

REPORTED DEVELOPMENTS

It has been reported that the most potent inhibitors of EGF receptors inhibit EGF-induced proliferation of A431/clone 15 cells with little or no effect on the proliferation of such cells when induced by other growth factors. It has been reported also that erbstatin inhibits the autophosphorylation of the EGF receptor in membranes of A431 cells. Higher concentrations of erbstatin are required to inhibit cyclic adenosine 3',5'-monophosphate (cAMP)-dependent protein 15 kinase.

SUMMARY OF THE INVENTION

In accordance with the present invention, there is provided a method of inhibiting abnormal cell proliferation in a patient suffering from a disorder characterized by such proliferation comprising the administration to a patient of an EGF and/or PDGF receptor inhibiting effective amount of a bis mono- and/or bicyclic aryl compound exhibiting protein a ring system containing 0-4 hetero atoms, said compound being optionally substituted or polysubstituted.

Another aspect of the present invention relates to pharmaceutical compositions comprising, in admixture with a pharmaceutically acceptable carrier, a pharmaceutically effective amount of a compound of the aforementioned type Another aspect of this invention comprises compounds useful in the practice of the present method.

With respect to the method aspects of this invention, the compounds described by Formula I below constitute a class of the aforementioned bis mono- and/or bicyclic aryl, heteroaryl, carbocyclic or heterocarbocyclic compounds for use in the practice of the present invention:




Ar I and Ar II are independently a substituted or unsubstituted mono- or bicyclic ring, said rings optionally substituted with 0 to about 3 R groups; and


X is (CHR₁)_{0.4} or (CHR₁)_m—Z—(CHR₁)_n where Z is O, NR', S, SO or SO2, m and n are 0-3 and m+n=0-3 and R2 and R' are independently hydrogen or alkyl; or a pharmaceutically acceptable sait thereof.

Preferably, AR I is a substituted or unsubstituted mono- or bicyclic aryl or heteroaryl ring system of about 5 to about 12 atoms and where each monocyclic ring may contain 0 to about 3 hetero atoms, and each bicyclic ring may contain 0 to about 4 hetero atoms selected from N, O and S provided said hetero atoms are not vicinal oxygen and/or sulfur atoms and where the substituents may be located at any appropriate position of the ring system and are described by R.;


Ar II may be as described for Ar I or at least one ring is substituted or unsubstituted saturated carbocyclic of about 3 to about 7 atoms where each monocyclic ring may contain 0 to about 2 hetero atoms, and each bicyclic ring may contain 0 to about 4 hetero atoms selected from N, O and S provided said hetero atoms are not vicinal oxygen and/or sulfur atoms and where the substituents may be located at



CAS REGISTRY



Chemistry & Biology, Vol. 12, 385-395, 2005



CAS REGISTRY








结构检索的原理与示例

专利中物质的标引方式:

- 具体物质[Specific Substance]:
- 一以具体化学结构陈述的特定物质,会被分配CAS RN
- 预测性物质[Prophetic Substance]:
- —使用Markush结构陈述的预测物质,一个Markush可以陈述上百或上千个化学物质
- 一被Markush结构包含,但未被实施或呈现在表格、权利要求书或说明书中的结构,不会被CAS分配CAS Registry Number
- Markush检索,能检索到通过结构检索检不到的专利









例:此结构是否已被相关文献披露?是否被包含在已公开专利文献的通式结构中?



先在CAS Registry中进行物质结构检索






Query


Exact Structure, Substructure结果为0






先在CAS Registry中进行物质结构检索








Similarity结果中物质最大相似度 仅为73%








再在CAS Markush中进行物质Markush结构检索







CAS科学家对专利原文中的Markush结构进行直观标引



Query structure

Indexed structure

Markush structure

What is claimed is:

 Compound represented by the following Chemical formula 1 or Chemical formula 2, an enantiomer thereof, a diastereomer thereof, or a pharmaceutically acceptable salt thereof:

[Chemical formula 1]
$$X_3 - X^2$$
 $X_1 - X_2$

or

[Chemical formula 2] $X_3 \xrightarrow{Y_2} Y \xrightarrow{Y_2} R^1$

wherein

X1 is O, S or -N(CH2CH3)-,

X2 and X3 are each independently N or CH,


 $\begin{array}{lll} Y \text{ is absent, or; is } -CH_2-; -CH_2NH-; -C(=0)-; \\ -CH_2CH_2-; -NH-; -NHC(=0)-; -C(=0) \\ NH-; -CH(CH_3)-; -CF_2-; -CH(OCH_3)-; \\ -CH_2O-; -N(CH_3)-; \text{ or } -CH_2NHC(=0)-, \end{array}$


Z is absent, or, is —CH₂S—; —CH₂S(=O)—; —CH₂NH—; —CH(R^O)S—; —CH₂CH₂S—; —CH₂N (CH₃)—;

Re is benzene.

R¹ is

benzene unsubstituted, or substituted with one or more selected from the group consisting of halogen, linear or branched C₁₋₄ alkyl, C₃₋₆ cycloalkyl, —OCF₃, —CF₃, —CHF₂, —OH, phenoxy, phenyl, C₁₋₄ alkoxy, —CN, —NH₂, and —N(CH₃);






pyridine unsubstituted, or substituted with halogen; naphthalene unsubstituted, or substituted with $C_{1.4}$ alkoxy; benzotriazole; quinoline or isoquinoline unsubstituted, or substituted with $C_{1.4}$ alkyl, $C_{1.4}$ alkoxy or halogen; indazole unsubstituted, or substituted with $C_{1.4}$ alkyl; $C_{3.6}$ cycloalkyl; benzothiophene; benzofuran; indole unsubstituted, or substituted with $C_{1.4}$ alkyl; or thiophene,


R^a is halogen; linear or branched C₁₋₄ alkyl; OCF₃; CF₃; or unsubstituted benzene.

Rc is benzene

n is an integer in the range of 0 to 3,



C_{1*4} alkyl; naphthalene unsubstituted, or substituted with halogen;





benzene unsubstituted, or substituted with one or more selected from the group consisting of halogen, linear or branched C₁₋₄ alkyl, C₃₋₆ cycloalkyl, —OCF₃, —CF₃, —CH₂, —OH, phenoxy, phenyl, C₁₋₄ alkoxy, —CN, —NH₂, and —N(CH₃);



benzofuran unsubstituted, or substituted with halogen; benzodioxole unsubstituted, or substituted with halogen; qui-

US 2020/0031816 A1

Jan. 30, 2020

107

noline or isoquinoline unsubstituted, or substituted with halogen; pyrazole unsubstituted, or substituted with linear or branched $C_{1,4}$ alkyl or halogen; indole substituted with $C_{1,4}$ alkyl; or imidazopyridine,

kyl; or influedayprinter, Rb is benzene unsubstituted, or substituted with one or more selected from the group consisting of linear C₁₋₄ alkyl; and halogen; linear C₁₋₄ alkyl; branched C₃-4 alkyl; —OCH₃; S-membered or 6-membered heteroaryl comprising N, O or S; cycloalkyl of 5 to 7 carbon atoms; —C(=O)CH₃; —OR^c; —C(=O) OCH₃; —CH₃, —OR^c; —C(=O) OCH₃; —CH₃, —OCH₃, —OH; —N(CH₃) 2; —C(=O)—OH; pyrrolidine; piperidine; pyrrole; furan; thiophene; morpholine; C₁₋₄ alkoxy substituted with morpholine; —NRdRe (wherein Rd is H or methyl, and Re is —CH₂CH₂OCH₃ or —CH₂CH₂Ph); or halogen.

R° is benzene unsubstituted, or substituted with halogen; C₁₋₄ alkyl; or halogen, and

m is an integer in the range of 0 to 2.

 R^{α} is C_{1-4} alkyl; halogen; or unsubstituted benzene, R^{σ} is benzene,


n is an integer in the range of 0 to 3, R² is





CAS PatentPak: 查看专利中重要的物质信息

WO2018062978





大纲


- CAS SciFinder数据介绍
- 纳米储能材料的研究调研与追踪
- 生物、催化和医药研究的物质根基
- 结构视角下的专利风险规避
- 制备反应研究的技术支撑








结构编辑器: 绘制反应工具








例1:双膦配体钴催化剂可以催化哪些类型










Group by Transformation:锁定反应类型







快速获取各类催化反应类型

1. Addition of Alkenes/ Alkynes to Alkenes/ Alkynes/ Nazarov Cyclization
 552 Reactions

2. Diels-Alder Reaction and Retro-Diels-Alder Reaction
352 Reactions

3. Addition of Organometallics to Unactivated Double or Triple Bonds
196 Reactions

$$R^{2} \quad R^{4} \qquad \qquad R^{2} \quad R^{4}$$

$$R^{1} = R^{2} \quad + \quad R - M \qquad \longrightarrow \qquad \begin{matrix} M & R^{2} & R^{4} \\ R^{1} & R^{2} & R^{4} \end{matrix}$$

4. Cyclotrimerization and Cyclotetramerization of Alkynes 190 Reactions

5. Coupling of Aryl Compounds with Arylboronic Acid Derivatives/ Suzuki Coupling 140 Reactions

$$Ar-Y + Ar^1-B$$
OR
OR
 $cat.$
 $Ar-Ar^1$

Y = OCOR', OSO₂R', Halogen

6. Arylation and Alkylation of Alkenes/ Heck Reaction
138 Reactions

$$R \rightarrow CH_2 + Ar-Y \xrightarrow{cat.} R \rightarrow CH-Ar$$

 $Y = OCOR', OSO_2R', Halogen$


7. Reduction of Double or Triple Bonds/ Hydrogenation 110 Reactions


R¹ R³ H₂ H





查看反应信息











例2:聚乙二醇单烯丙基醚的合成与修饰








获得聚乙二醇单烯丙基醚的合成制备反应







聚乙二醇单烯丙基醚的改性修饰








Refine: 精炼烯烃接枝后的结构变化

OK Cancel








Search type: Substructure

C H O S N P CI Br F I Si

00000


聚乙二醇单烯丙基醚的羟基修饰








例3: 生物转化反应











查看生物催化酶








细胞色素P450酶可以催化哪些反应












Group by Transformation: 一键浏览反应类型













利用SciPlanner设计拟合成反应路线








SciPlanner工作界面








SciPlanner工作界面








SciPlanner工作界面







SciPlanner——设计拟合成的反应路线







总结:

- CAS全面的数据内容、化学相关的广泛交叉学科覆盖和科学家的增值标引;
- 主题词构建及候选项的选择;设置提醒,及时跟踪最新研究进展;
- Analyze: CA Section Title锁定学科主题, Index Term精炼核心研究点; Categorize: 高效、 精准锁定核心研究点;
- 各类物质的检索方法;结构编辑器的灵活应用;结构检索和Markush检索的数据基础,对规避专利风险的帮助;
- 基于物质和反应的关联,灵活获取反应信息;Substance Role, Reaction Role一键锁定物质在文献中和反应中的角色;Group by Transformation高效获取反应类型;SciPlanner根据感兴趣的反应自主设计拟合出反应路线。

谢 谢 关 注!



美国化学文摘社北京代表处

ACS International, Ltd. – Representing CAS Unit 1010, Tower B, Raycom InfoTech Park 2 Kexueyuan Nanlu, Haidian District, Beijing, China

+86-10-6250 8026/7

cas.org











